| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Nour Zaïmia, Joelle Obeid, Annie Varrault, Julia Sabatier, Christophe Broca, Patrick Gilon, Safia Costes, Gyslaine Bertrand, Magalie A Ravie. GLP-1 and GIP receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function. Cell reports. vol 42. issue 11. 2023-10-28. PMID:37897727. |
in mouse β cells, arrb2 dampens insulin secretion by partially uncoupling cyclic amp (camp)/protein kinase a (pka) signaling at physiological doses of glp-1, whereas at pharmacological doses, the activation of extracellular signal-related kinase (erk)/camp-responsive element-binding protein (creb) requires arrb2. |
2023-10-28 |
2023-11-08 |
mouse |
| Fatih Altintas, Sadettin Caliskan, Melek Tunc-Ata, Emine Kilic-Toprak, Onur Tokgun, Neslihan Esra Avci, Vural Kucukata. Investigation of fructose consumption on hippocampal insulin and glucagon-like peptide-1 receptors, and metabolic effects in rats. Iranian journal of basic medical sciences. vol 26. issue 11. 2023-10-27. PMID:37886000. |
the goal of this study is to aim at the basal plasma levels of lipid profile, insulin, glp-1, and homa-ir, as well as the mrna and protein expression of neuroprotective molecules such as insr and glp-1r in wistar rats fed a high fructose diet. |
2023-10-27 |
2023-11-08 |
rat |
| Mona Mashayekhi, Hui Nian, Dustin Mayfield, Jessica K Devin, Jorge L Gamboa, Chang Yu, Heidi J Silver, Kevin Niswender, James M Luther, Nancy J Brow. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes. Diabetes. 2023-10-24. PMID:37874653. |
sitagliptin increased endogenous glp-1 and gip without altering insulin sensitivity or fasting glucose, but decreased post-prandial glucose and glucagon. |
2023-10-24 |
2023-11-08 |
Not clear |
| Mona Mashayekhi, Hui Nian, Dustin Mayfield, Jessica K Devin, Jorge L Gamboa, Chang Yu, Heidi J Silver, Kevin Niswender, James M Luther, Nancy J Brow. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes. Diabetes. 2023-10-24. PMID:37874653. |
thus, liraglutide exerts rapid, weight lossindependent, glp-1r-dependent effects on insulin sensitivity that are not achieved by increasing endogenous glp-1. |
2023-10-24 |
2023-11-08 |
Not clear |
| Jing Xu, Peng Chen, Dongzhi Wu, Qiang Zhou, Sijie Chen, Xiang Ding, Hongping Xion. The novel GLP-1/GIP dual agonist DA3-CH improves rat type 2 diabetes through activating AMPK/ACC signaling pathway. Aging. vol 15. 2023-10-18. PMID:37851373. |
da3-ch is a novel dual receptor agonist of glucagon like peptide-1 (glp-1) and glucose dependent insulin stimulating polypeptide (gip). |
2023-10-18 |
2023-11-08 |
rat |
| Naif H Ali, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Saud A Alnaaim, Athanasios Alexiou, Marios Papadakis, Asmaa A Khalifa, Hebatallah M Saad, Gaber El-Saber Batih. Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective. Journal of cellular and molecular medicine. 2023-10-17. PMID:37847125. |
also, nep inhibitors may inhibit dipeptidyl peptidase 4 (dpp4) expression, ameliorating insulin and glucagon-like peptide 1 (glp-1) levels. |
2023-10-17 |
2023-11-08 |
Not clear |
| Babu Shyamaladevi, Ipsita Dash, Ramya Badrachalam, Madhan Krishnan, Arjunkumar Panneerselvam, Sadhana Undr. An update on diagnosis and therapeutics for type-2 diabetes mellitus. Bioinformation. vol 19. issue 3. 2023-10-09. PMID:37808382. |
different categories of drugs such as insulin secretagogues, insulin sensitizers, alpha-glucosidase inhibitors, glp-1 agonists, dpp4 inhibitors, dual ppar agonists and others are used for its management. |
2023-10-09 |
2023-10-15 |
Not clear |
| Jennifer Erichsen, Suzanne Craf. Targeting immunometabolic pathways for combination therapy in Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). vol 9. issue 4. 2023-10-03. PMID:37786483. |
metabolic modulators that enhance insulin sensitivity and function, such as glp-1 receptor agonists, sglt2 inhibitors, and insulin itself have been shown to improve immune function and reduce chronic inflammation. |
2023-10-03 |
2023-10-07 |
Not clear |
| Ozlem Zeynep Akyay, Zeynep Canturk, Alev Selek, Berrin Cetinarslan, İlhan Tarkun, Yagmur Cakmak, Canan Baydemi. The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus. Medicine. vol 102. issue 39. 2023-09-29. PMID:37773814. |
this study aimed to compare the effects of glp-1 receptor analogs exenatide and insulin glargine treatment on bone turnover marker levels and bone mineral density (bmd) in postmenopausal female patients with t2dm. |
2023-09-29 |
2023-10-07 |
human |
| Aleksandra Szczesnowicz, Anna Szeliga, Olga Niwczyk, Gregory Bala, Blazej Meczekalsk. Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies. Journal of clinical medicine. vol 12. issue 18. 2023-09-28. PMID:37762856. |
glp-1 receptor agonists cause insulin release in a glucose-dependent manner, yielding clinical benefits such as heightened satiety, reduced appetite, and appetite regulation. |
2023-09-28 |
2023-10-07 |
Not clear |
| Ryan J Jalleh, Chinmay S Marathe, Laurence G Trahair, Karen L Jones, Michael Horowit. A Biphasic Glucose Response during an Oral Glucose Tolerance Test Is Associated with Greater Plasma Insulin and GLP-1 Responses and a Reduction in 1-Hour Glucose but Does Not Relate to the Rate of Gastric Emptying in Healthy, Older Adults. Nutrients. vol 15. issue 18. 2023-09-28. PMID:37764673. |
a biphasic glucose response during an oral glucose tolerance test is associated with greater plasma insulin and glp-1 responses and a reduction in 1-hour glucose but does not relate to the rate of gastric emptying in healthy, older adults. |
2023-09-28 |
2023-10-07 |
Not clear |
| Anubhav Pratap-Singh, Yigong Guo, Alberto Baldelli, Anika Sing. Concept for a Unidirectional Release Mucoadhesive Buccal Tablet for Oral Delivery of Antidiabetic Peptide Drugs Such as Insulin, Glucagon-like Peptide 1 (GLP-1), and their Analogs. Pharmaceutics. vol 15. issue 9. 2023-09-28. PMID:37765234. |
concept for a unidirectional release mucoadhesive buccal tablet for oral delivery of antidiabetic peptide drugs such as insulin, glucagon-like peptide 1 (glp-1), and their analogs. |
2023-09-28 |
2023-10-07 |
Not clear |
| Anubhav Pratap-Singh, Yigong Guo, Alberto Baldelli, Anika Sing. Concept for a Unidirectional Release Mucoadhesive Buccal Tablet for Oral Delivery of Antidiabetic Peptide Drugs Such as Insulin, Glucagon-like Peptide 1 (GLP-1), and their Analogs. Pharmaceutics. vol 15. issue 9. 2023-09-28. PMID:37765234. |
injectable peptides such as insulin, glucagon-like peptide 1 (glp-1), and their agonists are being increasingly used for the treatment of diabetes. |
2023-09-28 |
2023-10-07 |
Not clear |
| Anubhav Pratap-Singh, Yigong Guo, Alberto Baldelli, Anika Sing. Concept for a Unidirectional Release Mucoadhesive Buccal Tablet for Oral Delivery of Antidiabetic Peptide Drugs Such as Insulin, Glucagon-like Peptide 1 (GLP-1), and their Analogs. Pharmaceutics. vol 15. issue 9. 2023-09-28. PMID:37765234. |
this communication describes the current state of the art with respect to the creation of nanoparticles containing peptides such as insulin, glucagon-like peptide 1 (glp-1), and their agonists, and theorizes the production of mucoadhesive unidirectional release buccal tablets or films. |
2023-09-28 |
2023-10-07 |
Not clear |
| Femina Patel, Arnold Gan, Karen Chang, Kenneth J Veg. Acute Pancreatitis in a Patient Taking Semaglutide. Cureus. vol 15. issue 8. 2023-09-21. PMID:37731423. |
the semaglutide and cardiovascular outcomes in patients with type 2 diabetes (sustain-6) trial showed that semaglutide, a glucagon-like peptide-1 receptor agonist (glp-1 ra), is effective in managing type 2 diabetes by stimulating insulin secretion and promoting weight loss. though recent evidence suggests no increased risk of acute pancreatitis (ap) with subcutaneous semaglutide use, some studies report an increase in pancreatic inflammation with glp-1 ras. we present a case of ap in a patient recently started on subcutaneous semaglutide for type 2 diabetes. as glp-1 ra use increases, clinicians should be aware of their potential to cause acute pancreatitis. |
2023-09-21 |
2023-10-07 |
Not clear |
| Ziwen He, Jingyan Guo, Huiwen Zhang, Jingjing Yu, Yiqing Zhou, Yajun Wang, Ting Li, Meiqiu Yan, Bo Li, Yigong Chen, Suhong Chen, Guiyuan Lv, Jie S. Atractylodes macrocephala Koidz polysaccharide improves glycolipid metabolism disorders through activation of aryl hydrocarbon receptor by gut flora-produced tryptophan metabolites. International journal of biological macromolecules. 2023-09-20. PMID:37729987. |
glp-1 activated the pancreatic glp-1r/p-creb signaling pathway to ameliorate β-cell injury and improve insulin resistance. |
2023-09-20 |
2023-10-07 |
rat |
| Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, Angelo Cignarelli, Suetonia Cressida Palmer, Patrizia Natale, Giovanni F M Strippoli, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgin. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. EClinicalMedicine. vol 64. 2023-09-18. PMID:37719418. |
innovative glp-1 receptor agonist (glp-1ra)-based treatment strategies-such as tirzepatide, glp-1ra plus basal insulin fixed-ratio combinations [frc], glp-1ra plus sodium glucose cotransporter-2 inhibitors [sglt-2i] combinations, and high-dose glp-1ra-have been listed among the most efficacious options for type 2 diabetes management. |
2023-09-18 |
2023-10-07 |
Not clear |
| Nan Wu, Guohua A. A Quantitative Systems Pharmacology Model of the Incretin Hormones GIP and GLP1, Glucagon, Glucose, Insulin, and the Small Molecule DPP-4 Inhibitor, Linagliptin. Journal of pharmaceutical sciences. 2023-09-16. PMID:37716531. |
in the current study, we established a comprehensive quantitative systems pharmacology (qsp) model using linagliptin as the model drug, where drug disposition, drug intervention on dipeptidyl peptidase-4 (dpp-4), glucose-dependent insulinotropic peptide (gip), glucagon-like peptide-1 (glp-1), glucagon, glucose, and insulin are integrated together with the cross talk and feedback loops incorporated among the whole glycemic control system. |
2023-09-16 |
2023-10-07 |
human |
| Sohum Sheth, Aashay Patel, Marco Foreman, Mohammed Mumtaz, Akshay Reddy, Ramy Sharaf, Siddharth Sheth, Brandon Lucke-Wol. The protective role of GLP-1 in neuro-ophthalmology. Exploration of drug science. vol 1. issue 4. 2023-09-15. PMID:37711214. |
this article describes glp-1 peptide characteristics and the mechanisms mediating its known role in increasing insulin, decreasing glucagon, delaying gastric emptying, and promoting satiety. |
2023-09-15 |
2023-10-07 |
Not clear |
| Melek Tunc-Ata, Zeynep Mine Altunay, Aysel Alphan, Vural Kucukata. Effect of insulin on IR and GLP1-R expressions in HT22 cells. Medical oncology (Northwood, London, England). vol 40. issue 10. 2023-09-15. PMID:37712993. |
glucagon-like peptide 1 (glp-1) has a variety of functions including neuroprotection, support for neurogenesis, and increasing insulin signal. |
2023-09-15 |
2023-10-07 |
mouse |